EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Efficacy of HLX02‐Based Neoadjuvant Therapy in HER2‐Positive Breast Cancer: Clinical Insights and Future Directions

Zhengzhi Zhu iD, Jing Wang iD, Shikai Hong, Hong Gao iD, Jianjun Liu, Kuojun Ren iD, Shuhan Wang, Shengying Wang, Guoping Sun iD

The Breast Journal · 2025

DOI: 10.1155/tbj/1653319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Breast Journal, 2025. Verfasst von Zhengzhi Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The efficacy of HLX02, a trastuzumab biosimilar, in combination with chemotherapy for treating metastatic breast cancer (BC) has been established as equivalent to the reference Herceptin. This study aimed to assess the treatment response of HLX02‐based neoadjuvant therapy in HER2‐positive BC, with a focus on HR‐positive versus HR‐negative subgroups. Additionally, we investigated the potential role of a CDK4/6 inhibitor in combination with anti‐HER2 therapy.

Methods

This retrospective study included HER2‐positive BC patients who received HLX02‐based neoadjuvant therapy followed by curative surgery at Anhui Provincial Cancer Hospital between March 2021 and August 2023. Pathological complete response (pCR) rates were analyzed, and subgroup analyses evaluated predictors of pCR. In vitro experiments using BT‐474 and MCF‐7 cell lines assessed the effects of combining CDK4/6 inhibitors with anti‐HER2 therapy on cell viability and apoptosis.

Results

The study included 67 patients with a median age of 53 years. The overall pCR rate was 53.73%, with higher pCR rates observed in HR‐negative patients compared to HR‐positive patients (63.89% vs. 41.94%). Dual HER2 blockade with HLX02 and pertuzumab was associated with a numerically improved pCR rate (62.16%). ER expression significantly increased post‐treatment, potentially indicating treatment resistance mechanisms. In vitro, the combination of CDK4/6 inhibitors with anti‐HER2 therapy significantly reduced cell viability and promoted apoptosis in HR‐positive, HER2‐positive cell lines.

Conclusion

HLX02 demonstrates real‐world efficacy as part of neoadjuvant therapy for HER2‐positive BC, especially in HR‐negative patients. The lower pCR rate in HR‐positive patients highlights the need for additional strategies. Combining CDK4/6 inhibitors with anti‐HER2 therapy presents a promising approach for HR‐positive HER2‐positive patients, warranting further clinical validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoadjuvant TherapyErb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedRetrospective StudiesAdultAgedCyclin-Dependent Kinase 4Treatment OutcomeCyclin-Dependent Kinase 6

Stichwörter der Autor:innen

CDK4/6 inhibitorHER2-positiveHLX02HR-positiveanti-HER2 therapybreast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6ERBB2 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Breast Center, Anhui Provincial Cancer Hospital, West District of The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.

ORCID-Profile: Zhengzhi Zhu, Jing Wang, Hong Gao, Kuojun Ren, Guoping Sun

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, Z., Wang, J., Hong, S., Gao, H., Liu, J., Ren, K., Wang, S., Wang, S., & Sun, G. (2025). Real‐World Efficacy of HLX02‐Based Neoadjuvant Therapy in HER2‐Positive Breast Cancer: Clinical Insights and Future Directions. The Breast Journal. https://doi.org/10.1155/tbj/1653319

Vancouver

Zhu Z, Wang J, Hong S, Gao H, Liu J, Ren K, et al. Real‐World Efficacy of HLX02‐Based Neoadjuvant Therapy in HER2‐Positive Breast Cancer: Clinical Insights and Future Directions. The Breast Journal. 2025. doi:10.1155/tbj/1653319

BibTeX
@article{Zhu2025,
  author = {Zhu, Zhengzhi and Wang, Jing and Hong, Shikai and Gao, Hong and Liu, Jianjun and Ren, Kuojun and Wang, Shuhan and Wang, Shengying and Sun, Guoping},
  title = {Real‐World Efficacy of HLX02‐Based Neoadjuvant Therapy in HER2‐Positive Breast Cancer: Clinical Insights and Future Directions},
  journal = {The Breast Journal},
  year = {2025},
  doi = {10.1155/tbj/1653319}
}
Kostenlos starten →